Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
-0.61% $4.87
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 8.50 mill |
EPS: | -36.60 |
P/E: | -0.130 |
Earnings Date: | Mar 27, 2024 |
SharesOutstanding: | 1.745 mill |
Avg Daily Volume: | 0.0207 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.130 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.130 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 4.53 - 5.27 ( +/- 7.51%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Hague Henry R Iii | Sell | 170 | Common shares |
2024-02-27 | Hague Henry R Iii | Sell | 411 | Common shares |
2024-01-19 | Wilches Julian | Sell | 131 | Common shares |
2024-01-19 | Fajardo Andres | Sell | 1 561 | Common shares |
2023-12-20 | Fajardo Andres | Sell | 177 | Common shares |
INSIDER POWER |
---|
81.26 |
Last 96 transactions |
Buy: 6 473 147 | Sell: 5 259 866 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.87 (-0.61% ) |
Volume | 0.0454 mill |
Avg. Vol. | 0.0207 mill |
% of Avg. Vol | 219.66 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment is engaged in formulating, manufacturing, marketing, selling, distributing, and commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.